Schirinzi T, Di Lazzaro G, Sancesario GM, Summa S, Petrucci S, Colona VL, et al
This combination of peptides creates a triple threat for healing, accelerating recovery and improving overall outcomes
It has been estimated the prevalence of GERD symptoms in the general population may be up to 30% in the U.S.[125] but other studies show it could be as high as 34% to 40%.[126] The standard treatment for this condition continues to be the use of a powerful class of medications known as proton-pump inhibitors (PPIs)
It is important to note that Saxenda has not been specifically studied in cardiovascular outcome trials in the same manner as some other GLP-1 receptor agonists
Store reconstituted vials at 35.6-46.4F (2-8C) and protect from light
Metabolic Efficiency : Improves insulin sensitivity and energy utilization ( 4, 5 )